Fibromyalgia - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fibromyalgia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Fibromyalgia - Pipeline Review, H1 2015', provides an overview of the Fibromyalgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibromyalgia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fibromyalgia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fibromyalgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibromyalgia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibromyalgia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fibromyalgia Overview 7
Therapeutics Development 8
Pipeline Products for Fibromyalgia - Overview 8
Pipeline Products for Fibromyalgia - Comparative Analysis 9
Fibromyalgia - Therapeutics under Development by Companies 10
Fibromyalgia - Therapeutics under Investigation by Universities/Institutes 12
Fibromyalgia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Fibromyalgia - Products under Development by Companies 16
Fibromyalgia - Products under Investigation by Universities/Institutes 17
Fibromyalgia - Companies Involved in Therapeutics Development 18
Collegium Pharmaceutical, Inc. 18
Daiichi Sankyo Company, Limited 19
Eli Lilly and Company 20
Merck & Co., Inc. 21
Sumitomo Dainippon Pharma Co., Ltd. 22
SWITCH Biotech LLC 23
Tonix Pharmaceuticals Holding Corp. 24
Zynerba Pharmaceuticals, Inc. 25
Fibromyalgia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
droxidopa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
duloxetine hydrochloride DR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
milnacipran hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mirogabalin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mirtazapine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
naltrexone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PRTT-200 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SWT-06101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TD-9855 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TNX-102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ZYN-001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Fibromyalgia - Recent Pipeline Updates 53
Fibromyalgia - Dormant Projects 67
Fibromyalgia - Discontinued Products 68
Fibromyalgia - Product Development Milestones 69
Featured News & Press Releases 69
Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia 69
Sep 29, 2014: Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia 69
May 12, 2014: Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia 70
Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia 71
Dec 10, 2013: Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study 72
Nov 26, 2013: Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 72
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 73
Sep 16, 2013: Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients 73
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 74
Mar 11, 2013: Tonix Completes Pre-Phase III Meeting With FDA For TNX-102 SL In Fibromyalgia 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Tables
Number of Products under Development for Fibromyalgia, H1 2015 8
Number of Products under Development for Fibromyalgia - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Fibromyalgia - Pipeline by Collegium Pharmaceutical, Inc., H1 2015 18
Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 19
Fibromyalgia - Pipeline by Eli Lilly and Company, H1 2015 20
Fibromyalgia - Pipeline by Merck & Co., Inc., H1 2015 21
Fibromyalgia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22
Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2015 23
Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 24
Fibromyalgia - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Fibromyalgia Therapeutics - Recent Pipeline Updates, H1 2015 53
Fibromyalgia - Dormant Projects, H1 2015 67
Fibromyalgia - Discontinued Products, H1 2015 68